Get the Stockscreener App
130.41
0.22%
0.29
After Hours:
130.41
Illumina Inc stock is traded at $130.41, with a volume of 1.08M.
It is up +0.22% in the last 24 hours and down -0.75% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$130.12
Open:
$130.12
24h Volume:
1.08M
Relative Volume:
0.64
Market Cap:
$20.80B
Revenue:
$4.43B
Net Income/Loss:
$-3.04B
P/E Ratio:
-4.9008
EPS:
-26.61
Net Cash Flow:
$357.00M
1W Performance:
+0.24%
1M Performance:
-0.75%
6M Performance:
-5.03%
1Y Performance:
-5.00%
1-Day Range:
$128.03
$131.14
1-Week Range:
$125.93
$134.51
52-Week Range:
$89.00
$148.19
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina Inc. stock rises Monday, still underperforms market - MarketWatch
Illumina's SWOT analysis: sequencing leader faces headwinds but eyes growth - Investing.com India
Shareholders in Illumina (NASDAQ:ILMN) are in the red if they invested three years ago - Yahoo Finance
Washington, DC’s secret weapon for RSV surveillance - Illumina
Illumina's SWOT analysis: sequencing leader faces headwinds but eyes growth - Investing.com
Sei Investments Co. Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Increases Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
When (ILMN) Moves Investors should Listen - Stock Traders Daily
Thrivent Financial for Lutherans Has $6.29 Million Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Stake Lowered by Decheng Capital LLC - MarketBeat
Lab-on-a-Chip and BIOCHIP Market May See a Big Move| Illumina, Agilent Technologies, Perkin Elmer - openPR
Michael C. Burgess makes a stock sale in Illumina, Inc. By Investing.com - Investing.com Australia
Michael C. Burgess makes a stock sale in Illumina, Inc. By Investing.com - Investing.com Canada
Michael C. Burgess makes a stock sale in Illumina, Inc. - Investing.com India
Michael C. Burgess makes a stock sale in Illumina, Inc. - Investing.com
Michael C. Burgess makes a stock sale in Illumina, Inc. By Investing.com - Investing.com UK
Point72 Asia Singapore Pte. Ltd. Acquires 19,510 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success - Seeking Alpha
Gene Sequencing Market SWOT Analysis by Leading Key Players: Agilent Technologies, Illumina, QIAGEN - openPR
The past three years for Illumina (NASDAQ:ILMN) investors has not been profitable - Simply Wall St
DNA Sequencing Market Industry Insights: Market Size, Share, - openPR
American Century Companies Inc. Sells 24,544 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Westwood Holdings Group Inc. Buys New Shares in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
DRW Securities LLC Takes $1.94 Million Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
The Future Is Bright Campaign Expands Into China - ReportAlert.info
14,559 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Symmetry Investments LP - MarketBeat
Illumina partners with Africa CDC to strengthen sequencing capacity for COVID-19 surveillance in Africa - africacdc.org
Amalgamated Bank Has $8.41 Million Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
EU’s Illumina Defeat Sparks Dutch Call for More Deal Powers - MSN
EU’s Illumina Defeat Sparks Dutch Call for More Deal Powers - Bloomberg
FY2024 EPS Estimates for Illumina, Inc. Boosted by Analyst (NASDAQ:ILMN) - MarketBeat
Mutual of America Capital Management LLC Purchases 67,122 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture - Yahoo Finance
EU Drops Microsoft-Inflection Probe After Illumina Ruling - Law360
Illumina, Inc. Expected to Post Q3 2025 Earnings of $1.12 Per Share (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Shares Bought by CCLA Investment Management - MarketBeat
Illumina Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
CSR News Feed | Explore the latest corporate social responsibility news from Illumina - Illumina
Primecap Management Co. CA Purchases 1,997,010 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Receives $151.05 Consensus Price Target from Analysts - MarketBeat
Syntax Bio Launches with Strategic Backing from Astellas Venture Management LLC and Illumina Ventures - Business Wire
Illumina, Inc. (NASDAQ:ILMN): A Non-Tech Stock With Long-Term Investment Potential - Yahoo Finance
Video: Highlighting the role of CGP in cancer treatment at ESMO 2024 - Illumina
Genotyping Assay Market Surges to USD 37.1 Billion by 2029 As Revealed In New Report - WhaTech
State of New Jersey Common Pension Fund D Sells 32,700 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Karina Katalina Moreno is living her dream - Illumina
Illumina, Inc. (NASDAQ:ILMN) Position Increased by Wilkins Investment Counsel Inc. - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Federated Hermes Inc. - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Goldman Thinks Illumina, Inc. (ILMN) Is A Long-Term AI Stock Set To Rally Eventually - Yahoo Finance
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):